Oncorena is developing a potentially curative therapy for metastatic renal cancer based on orellanine, a toxin from the Cortinarius family of mushrooms. Accidental intake of such mushrooms is well known to cause an acute renal failure, but no other toxic effects in other organs.
Pioneering preclinical research findings by the founders of Oncorena have shown that orellanine has a powerful killing effect on human metastatic kidney cancer in different experimental set ups. This discovery has ignited efforts to develop ONC175 (synthetic orellanine) into a first-in-class drug that potentially may revolutionize the treatment of metastatic renal cancer.
ONC175 (orellanine) initially will be examined in patients with metastatic renal cancer and dialysis due to chronic kidney disease. These patients have no remaining kidney function and need treatment of the metastatic disease. Thus, there is a high benefit-risk ratio as the patients may have therapeutic anti-tumor benefit without the risk of losing their renal function. If the curative potential is confirmed in these patients, the logical next step would be to expand into patients with metastatic renal cancer with remaining kidney function. This larger patient population would benefit from strategies to protect the healthy renal tissue. Currently, Oncorena are exploring such possibilities in collaboration with partners.
ONC175 is the synthetically produced active ingredient in orellanine
ONC175 is a first in class drug candidate and has no direct competition
ONC175 targets an orphan drug indication
ONC175 (orellanine) is expected to have positive effect on the two most common forms of kidney cancer: Clear-Cell Carcinoma and Papillary Renal Carcinoma. About 90 % of kidney cancer patients are affected by these types of cancer
ONC175 (orellanine) will be given as an intravenous infusion with the goal to provide superior long-term survival benefit compared to current treatments
ONC175 (orellanine) demonstrates an excellent three-year stability and process is scalable to commercial production
Orellanine is a highly kidney-specific substance is mainly found in Cortinarius orellanus and Cortinarius rubellus
The drug product ONC175, is the synthetically produced active ingredient
Based on preclinical findings, ONC175 likely has a favorable adverse event profile in patients on dialysis due to chronic kidney disease